Your browser does not support iframes.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced
that it will issue a press release on its fourth quarter and full year
2018 financial results on Wednesday, February 13, 2019 at 7:00 a.m. ET.
Following the release, Teva will conduct a conference call and live
webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-966-1396;
Israel 1-809-203-624 or International +44 (0) 2071 928000; passcode: 1174907.
For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: http://ir.tevapharm.com/.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website by calling United
States 1-866-331-1332; International +44 (0) 3333 009785; passcode: 1174907.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global
leader in generic medicines, with innovative treatments in select areas,
including CNS, pain and respiratory. We deliver high-quality generic
products and medicines in nearly every therapeutic area to address unmet
patient needs. We have an established presence in generics, specialty,
OTC and API, building on more than a century-old legacy, with a fully
integrated R&D function, strong operational base and global
infrastructure and scale. We strive to act in a socially and
environmentally responsible way. Headquartered in Israel, with
production and research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of patients.
Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding Teva's epinephrine injection USP, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that could
cause our future results, performance or achievements to differ
significantly from that expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to:
View source version on businesswire.com:
Kevin C. Mannix(215)
Ran Meir972 (3) 9267516
658-0237Elizabeth DeLuca(267) 468-4329
Yonatan Beker972 (54) 888 5898
Source: Teva Pharmaceutical Industries Ltd.